Ibrutinib (Induction) Clinical Trials

1 actively recruiting trial

Also known as: Imbruvica

Pipeline

Phase 3: 1

Top Sponsors

Prof. Dr. M. Dreyling (co-chairman)1

Indications

Mantle Cell Lymphoma1
Cancer1

Other1 trial

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.